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ABSTRACT
Objective: To evaluate whether intensive statin therapy in a
managed-care setting produces greater clinical beneﬁt than
more moderate statin use.
Methods: Adults hospitalized for a coronary heart disease
(CHD) event were identiﬁed from a longitudinal database of
pharmaceutical and medical claims. Propensity scores repre-
senting a patient’s likelihood of receiving statin therapy were
calculated. Statin-treated patients were those who received
statin therapy within 30 days of hospital discharge after a
CHD event, had been supplied with statin therapy for at least
10 days during the follow-up period, and received statin
therapy for at least 10 days before the ﬁrst recurrent CHD
event. Standard or intensive statin therapy was identiﬁed
according to low-density lipoprotein cholesterol reductions
expected with statin dose. Patients in the standard and inten-
sive groups were matched by propensity scores to patients
not receiving statin therapy after discharge. Patients in the
standard statin therapy group were also matched to patients
who received intensive statin therapy. Mortality rates after
hospital discharge were compared in all matched groups.
Results: Patients treated with standard therapy experienced
a 32% reduction in risk of death compared with patients not
receiving statin therapy (P = 0.003). Patients who received
intensive statin therapy after a CHD event experienced a
42% reduction in risk of mortality (P = 0.002) versus those
not receiving statin therapy. Compared with standard ther-
apy, intensive statin treatment further reduced the risk of
death by 29% (P = 0.020).
Conclusions: High risk CHD patients beneﬁt from intensive
statin therapy in a real-world, managed-care cohort, con-
ﬁrming the results of randomized clinical trials.
Keywords: coronary heart disease, managed-care programs,
mortality, statins.
Introduction
A number of large clinical trials have demonstrated
beneﬁcial effects of statin therapy in patients with a
history of cardiovascular disease (CVD) [1–4]. In addi-
tion, recent trials have observed greater cardiovascular
beneﬁt with intensive statin therapy than with more
moderate statin regimens [5–8]: the Arterial Biology
for the Investigation of Treatment Effects of Reducing
Cholesterol [5] and the Reversing Atherosclerosis with
Aggressive Lipid-lowering [7] studies demonstrated
reductions in measures of atherosclerotic progression
and the Pravastatin or Atorvastatin Evaluation and
Infection Therapy–Thrombosis in Myocardial Infarc-
tion 22 (PROVE IT–TIMI 22) [8] and the Treating to
New Targets (TNT) [6] trials demonstrated greater
reductions in cardiovascular events with intensive ver-
sus more moderate statin therapy.
In response to evidence from lipid-lowering trials,
guidelines have recommended increasingly rigorous
total cholesterol and low-density lipoprotein choles-
terol (LDL-C) goals in patients with established coro-
nary heart disease (CHD) [9–11]. In 2001, the Third
Report of the National Cholesterol Education Pro-
gram Adult Treatment Panel (NCEP ATP III) estab-
lished an LDL-C target of less than 100 mg/dL as a
minimal goal for patients with or at high risk of CHD
[9]. Nevertheless, in 2004, after the publication of the
results of the Heart Protection Study [12] and the
PROVE IT–TIMI 22 trial [8], both of which reported
signiﬁcant reductions in cardiovascular risk in high
CVD risk patients when LDL-C levels were lowered to
well below 100 mg/dL, the NCEP ATP III introduced
an optional LDL-C goal of less than 70 mg/dL for
“very high risk” patients [13]. Very high risk patients
include those with established CVD plus multiple
major CVD risk factors, diabetes, risk factors for the
metabolic syndrome, or patients with acute coronary
syndrome (ACS).
Because clinical trials are usually conducted in spe-
ciﬁc populations and use strictly speciﬁed procedures,
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the beneﬁts of statin therapy also need to be demon-
strated in a real-world setting. A recent claims-based
analysis that examined use of lipid-lowering medica-
tions, LDL-C reductions achieved, and LDL-C goal
attainment revealed that 56% of dyslipidemic patients
at risk of CHD were not treated with lipid-lowering
medications [14]. Results from observational studies in
hospital settings suggest that initiating statin therapy
immediately after a coronary event is indeed associated
with signiﬁcant reductions in recurrent coronary
events and death [15–17]. In one large prospective
cohort study, patients who initiated statin therapy
before or at the time of hospital discharge after an
acute myocardial infarction (MI) had a lower mortal-
ity rate than those who did not receive statin therapy
[17]. The study reported here went beyond this and
compared the clinical beneﬁts associated with intensive
versus moderate statin therapy in a managed-care pop-
ulation and was designed to evaluate whether, in a
managed-care population, statin therapy would confer
similar clinical beneﬁts to those obtained in clinical tri-
als and whether intensive statin therapy would pro-
duce greater clinical beneﬁt than more moderate statin
therapy.
Methods
Database
Data for the study were obtained from the PharMetrics
Patient-Centric Database, a longitudinal database that
comprises fully adjudicated medical and pharmaceuti-
cal claims for more than 43 million patients. The data-
base includes inpatient and outpatient diagnoses and
procedures and contains records of all prescriptions.
Patient demographics, including location, age, sex,
and health plan type, are also recorded.
The PharMetrics database records are representa-
tive of the commercially insured US population. To
secure unbiased reporting, health plans had to have
submitted data for all members to be included in the
database. Contributed data were quality checked to
ensure a standardized format and to minimize report-
ing errors.
Sample Selection
Figure 1 presents the application of the inclusion
and exclusion criteria. Patients were identiﬁed who
had been hospitalized for a CHD event between
January 1, 2000 and June 30, 2003. A CHD event
was deﬁned as 1 or more of the following: nonfa-
tal MI, resuscitated cardiac arrest, acute coronary
occlusion without MI, coronary artery bypass graft
(CABG), or percutaneous transluminal coronary
angioplasty.
The ﬁrst hospital discharge date after a CHD event
was deﬁned as the “index date.” The “preindex
period” was speciﬁed as the 12 months before the
index date. Follow-up was for a minimum of 1 month.
Patients had to have had no hospitalization for a CHD
event in the preindex period or within 10 days of hos-
pital discharge and data on all health-care utilization
had to be available. Patients also had to be continu-
ously eligible for drug beneﬁts during the entire pre-
index and follow-up periods. For inclusion in the
analyses, patients had to be aged more than 18 years
and, if they were not covered by Medicare “risk,” they
had to be less than 65 years of age. Additionally, the
duration of index hospitalization had to have been for
no more than 30 days and patients had to have had a
diagnosis or treatment of lipid disorders in the prein-
dex period, identiﬁed by ICD-9 codes ICD-9-CM
272.X, excluding 272.6.
Figure 1 Application of study inclusion and
exclusion criteria. After applying study inclusion
and exclusion criteria, there were a total of
13,715 patients in the database, of whom 9299
qualiﬁed as statin-treated patients and 4416 as
nonstatin-treated patients.
.
Total Patients Hospitalized with a Cardiac Event of Interest in the PharMetrics Database
95,785
Patients with a cardiac-related hospitalization between January 2000 and June 2003
77,015
Patients without a cardiac-related hospitalization in prior 12 months
69,972
All healthcare utilization available for patients
60,908
Health plan enrollment restrictions met 
(12 months prior, 1 month after cardiac event)
32,317
Valid data for age, gender, and region
31,950
Additional pre-matching criteria 
(e.g., >10 days supply for statin therapy)
13,715
9,299 Statin Patients 4,416 No Statin Patients
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Statin-treated patients were then identiﬁed. Patients
were regarded as statin-treated if they had received sta-
tin therapy within 30 days of the index date, had been
supplied with statin therapy for at least 10 days during
the follow-up period, and had received statin therapy
for at least 10 days before the ﬁrst CHD event. From
the statin-treated patients, two groups were then iden-
tiﬁed: an intensive statin therapy group and a standard
(mild-to-moderate LDL-C reduction) statin therapy
group. Intensive statin therapy was deﬁned as a target
LDL-C reduction of 40% or more, based on expected
reductions from the drug labeling. Regimens classiﬁed
as intensive therapy were atorvastatin 20 to 80 mg,
simvastatin 40 to 80 mg, lovastatin (including gener-
ics) 60 mg, and cerivastatin 0.8 mg. Standard statin
therapy was deﬁned as a target LDL-C reduction of
less than 40%, also based on expected reductions from
the drug labeling. Regimens classiﬁed as standard ther-
apy were atorvastatin 10 mg, simvastatin 5 to 20 mg,
pravastatin 10 to 80 mg, ﬂuvastatin 20 to 80 mg, lov-
astatin (including generics) 10 to 40 mg, and cerivas-
tatin 0.2 to 0.4 mg. Rosuvastatin and simvastatin/
ezetimibe combination treatment were not available
during this retrospective study period.
Matching Patients
Once all of these inclusion and exclusion criteria had
been applied, stepwise logistic regression analyses were
undertaken to create three matched cohorts (intensive
statin therapy vs. no statin, standard statin therapy vs.
no statin, intensive vs. standard statin therapy). Three
separate propensity models were utilized to support
the cohort matching. Patients in the intensive statin
group were matched on a 1:1 basis to patients not
receiving statin therapy based on the estimated pro-
pensity score for statin therapy [18,19]. A propensity
score represents a patient’s likelihood of receiving sta-
tin therapy. The independent variables in each model
included the demographic and preindex clinical char-
acteristics of the patients. The propensity scores were
then calculated by summing coefﬁcient values for these
potential confounding variables, which included sex,
payer type, geographic region, preindex presence of
CHD comorbidities, presence of comorbidities during
index hospitalization, preindex use of treatment for
lipid disorders, concomitant medications for selected
conditions, preindex CHD event diagnosis, CHD
event at index diagnosis, total preindex health-care
costs, total index hospitalization costs, index hospital-
ization length of stay, and days of follow up. Propen-
sity scores are a more reliable way of estimating effects
of treatment than linear or logistic regression because
of the transparency of the assumptions made to calcu-
late the scores [19].
Patients were then matched (Fig. 2). Where possi-
ble, each patient in the intensive statin dose group was
matched by propensity score to a patient not receiving
statin therapy after discharge. Patients in the intensive
statin therapy group were then matched to patients
receiving standard dose statin therapy. Standard statin
therapy group patients were similarly matched by pro-
pensity score (again, maximum difference ±0.01) to
patients receiving no statin. All unsuccessfully matched
patients were excluded from all analyses. The propen-
sity score was used to balance the covariates in the two
groups. At any value of the propensity score, covari-
ates were balanced between exposure groups and
therefore bias was reduced in a similar manner to a
randomization treatment strategy.
Consequently, this procedure resulted in the forma-
tion of three distinct matched cohorts: the standard
versus no-statin therapy cohort, the intensive versus
no-statin therapy cohort, and the intensive versus
standard statin therapy cohort.
Figure 2 Application of matching procedure.
Statin-treated patients were classiﬁed as receiv-
ing either standard or intensive therapy. Where
possible, patients in the standard and intensive
therapy groups were matched by propensity
score to patients from the no-statin group to
form two matched cohorts. A third matched
cohort comprised patients from the standard
statin therapy group that could be matched
with those from intensive therapy groups.
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Measures
Baseline demographic, clinical, and economic charac-
teristics of the study sample were summarized. Patients
were followed from the index date to the end of their
enrollment period in the health plan or the study end
date (i.e., September 30, 2003), whichever came ﬁrst.
All outcomes of interest were aggregated between the
patient’s index date and the end date.
Rates of all-cause mortality after hospital discharge
were compared between the arms of all three matched
cohorts. Death was deﬁned using a claims-based proxy
method [20]. Patients were assumed to have died if,
during the last month in which medical and pharmacy
claims were available before disenrollment, they were
recorded as having experienced a cardiac event, includ-
ing resuscitation, deﬁbrillation, cardiac complications,
cardiac arrest/failure, any hospitalization, emergency
room visit, ambulance service, cerebral death, or injec-
tion given to stimulate the heart.
Statistical Analyses
Comparisons of categorical variables were performed
using chi-square tests and comparisons of continuous
variables were performed using t tests. Risk of death
was estimated using a Cox proportional hazards
model. This model was used rather than simple regres-
sion analyses to take into account the time to event
when calculating the hazard ratio (HR) and to adjust
for differential follow up among patients. Selected
prognostic variables, such as age, sex, health plan type,
geographic region, type of CHD event, cardiovascular
diagnoses, comorbidities, and concomitant therapies,
were included in the risk models for additional preci-
sion supplementary to the propensity matching.
Results
The database contained 95,785 patients who were
hospitalized for a CHD event between January 1, 2000
and June 30, 2003. After applying exclusion criteria,
13,715 patients were available for matching (Fig. 1).
As a result of the matching procedure used, patients in
like arms could differ between the cohorts. For exam-
ple, a patient receiving intensive statin therapy may
have been matched to a patient receiving standard
therapy and so could be included in the intensive ver-
sus standard therapy cohort but may not have been
similar enough to any of the patients receiving no-sta-
tin therapy to be matched for the intensive versus no-
statin therapy cohort. The standard versus no-statin
therapy cohort comprised 4872 patients (2436
patients in each arm), the intensive versus no-statin
therapy cohort comprised 3376 patients (1688
patients in each arm), and the intensive versus stand-
ard statin therapy cohort comprised 6684 patients
(3342 patients in each arm) (Fig. 2).
Statins were the most common lipid-lowering
agents used before index hospitalization and were used
by 46.0% of patients in the standard versus no-statin
therapy cohort, 52.0% of patients in the intensive ver-
sus no-statin therapy cohort, and 65.2% of patients in
the intensive versus standard statin therapy cohort.
Fibrates were the next most common therapy (used by
7.5% of standard vs. no-statin cohort, 8.9% of inten-
sive vs. no-statin cohort, and 6.1% of intensive vs.
standard statin cohort), followed by niacin (2.1% of
standard vs. no-statin cohort, 2.6% of intensive vs. no-
statin cohort, and 2.5% of intensive vs. standard statin
cohort). A large proportion of patients received no
lipid-lowering medication at all (42.6% of standard
vs. no-statin cohort, 34.7% of intensive vs. no-statin
cohort, and 25.0% of intensive vs. standard statin
cohort). Differences in lipid-lowering medication use
between the arms of each cohort were small and not
statistically signiﬁcant.
Table 1 provides information for all of the matched
cohorts on the numbers of patients receiving each of
the statins from the index date. In all three matched
cohorts, atorvastatin was the statin received by the
highest proportion of patients, ranging from 40.5% of
all patients receiving standard statin therapy in the
standard versus no-statin cohort to 71.2% of all
patients receiving intensive statin therapy in the inten-
sive therapy versus standard statin therapy cohort
(Table 1). Very few patients received cerivastatin (2%
or fewer) in any statin arm as a result of its withdrawal
from the market in 2001.
Baseline Characteristics
Demographic characteristics for the three matched
cohorts are reported in Table 2. Only data for the
matched cohorts are presented in the table and not
data for the two arms of each cohort for reasons of
space, but differences between arms were minimal, as
expected, as a result of matching. There were only
three instances where there were signiﬁcant differences
Table 1 Statin regimens in the matched groups
Statin regimen
Versus no 
statin N (%)
Versus intensive 
statin therapy N (%)
Standard statin therapy
Atorvastatin 10 mg 987 (41) 1448 (43)
Simvastatin 5–20 mg 935 (38) 1107 (33)
Pravastatin 10–80 mg 366 (15) 587 (18)
Fluvastatin 20–80 mg 74 (3) 98 (3)
Lovastatin 10–40 mg† 41 (2) 49 (1)
Cerivastatin 0.2–0.4 mg* 33 (1) 53 (2)
Intensive statin therapy
Versus no 
statin N (%)
Versus standard 
statin therapy N (%)
Atorvastatin 20–80 mg 1124 (67) 2378 (71)
Simvastatin 40–80 mg 561 (33) 951 (28)
Cerivastatin 0.8 mg* 2 (<1) 11 (<1)
Lovastatin 60 mg† 1 (<1) 2 (<1)
*Cerivastatin was withdrawn from the market in 2001.
†Includes generics.
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between the arms of the cohorts. In the 1) standard
versus no-statin; and 2) intensive versus no-statin
cohorts, physician speciality differed signiﬁcantly
between the arms, with patients in the statin-treated
arms being more likely to see a cardiologist than non-
statin-treated patients (48.3% vs. 42.0%, standard vs.
no-statin therapy, respectively; 53.3% vs. 44.3%,
intensive vs. no-statin therapy, respectively; both
P < 0.001 for differences across physician specialities
between the arms of each cohort). In the intensive ver-
sus standard statin cohort, patients in the standard sta-
tin arm were older than those who received intensive
statin therapy (56.1 years vs. 55.6 years, P = 0.034).
There were no other signiﬁcant differences in demo-
graphic characteristics between the arms of the
matched cohorts.
The cause of index hospitalization for the majority
of patients was a nonfatal MI (62.2% in the standard
vs. no-statin therapy cohort, 63.1% in the intensive vs.
no-statin therapy cohort, 62.7% in the intensive vs.
standard statin therapy cohort) or a CABG procedure
(30.7% in the standard vs. no-statin therapy cohort,
30.0% in the intensive vs. no-statin therapy cohort,
33.2% in the intensive vs. standard statin therapy
cohort).
The most frequent index inpatient CHD comorbid-
ities are presented in Table 3 for all three matched
cohorts. As a result of matching, there were very few
differences in clinical baseline characteristics between
the arms of each cohort, so these data are not pre-
sented in Table 3. There were only four signiﬁcant
differences between the arms of the cohorts. In the
standard versus no-statin therapy matched cohort, sig-
niﬁcantly more patients in the no-statin arm had a
diagnosis of stroke during index hospitalization (3.0%
vs. 1.9%, P = 0.015) or experienced preindex, as an
outpatient, progressive, unstable angina (17.5% vs.
15.4%, P = 0.040) than patients in the statin arm. In
the intensive versus no-statin therapy matched cohort,
patients in the no-statin arm had a greater incidence
of preindex chronic renal failure (4.4% vs. 3.1%,
P = 0.047) than patients in the statin arm. In the inten-
sive versus standard statin therapy matched cohort,
patients in the standard statin therapy arm were more
likely to have experienced atrial arrhythmias during
the index hospitalization (2.8% vs. 2.1%, P = 0.047)
Table 2 Baseline demographic characteristics for all matched groups
Matched cohort:
standard vs.
no-statin therapy
Matched cohort:
intensive vs.
no-statin therapy
Matched cohort: 
intensive vs. standard
statin therapy
N (all patients) 4872 3376 6684
Mean age, years (SD) 58.9 (10.9) 56.7 (9.8) 55.9 (8.8)*
Male (%) 68.7 71.1 75.2
Mean 1 year preindex health-care costs, US$1000s (SD) 10.5 (19.5) 10.0 (19.8) 8.9 (15.9)
Geographic region (%) 18.0 16.8 15.3
Northeast 18.0 16.8 15.3
Midwest 49.7 51.5 54.9
South 25.1 24.1 21.7
West 7.2 7.6 8.1
Plan type (%) 52.8 46.2 42.5
HMO 52.8 46.2 42.5
Indemnity 2.2 2.8 2.6
POS 10.1 11.7 13.1
PPO 29.8 34.2 37.3
Other 0.0 0.0 0.0
Unknown 5.2 5.1 4.5
Payer type (%)
Commercial 60.0 65.2 68.3
Medicaid† 1.4 1.4 1.3
Medicare risk† 22.2 14.1 8.6
Medicare cost† 0.0 0.0 0.0
Self-insured 3.9 4.5 4.2
Other 0.0 0.0 0.0
Unknown 12.5 14.7 17.6
Physician speciality (%)**
FP/GP 10.7 11.6 11.4
Internal medicine 14.8 13.3 13.0
Cardiologist 45.2 48.8 53.1
Endocrinologist 1.6 1.5 1.7
Other 23.0 20.7 17.8
Unknown 4.7 4.2 3.0
*P < 0.05 for difference between arms of group; **P < 0.001 for the difference across physician specialities between the arms of the standard versus no-statin and of the intensive
versus no-statin group.
†Medicaid and Medicare patients were enrolled in Medicare Risk or Managed Medicaid offerings through managed health-care plans.
There were no signiﬁcant differences between the arms within any of the matched groups unless otherwise indicated. Differences are minimal as a result of matching.
FP, family practitioner; GP, general practitioner; HMO, health maintenance organization; POS, point of service; PPO, preferred provider organization.
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than those who were in the intensive statin therapy
arm. There were no other signiﬁcant differences in
clinical baseline characteristics between arms of any of
the cohorts.
Mortality Analyses
The crude mortality rates for all three matched cohorts
are presented in Figure 3. In all statin versus no statin
comparisons, patients in the statin arms experienced a
lower risk of death than patients in the no-statin arm.
In addition, intensive statin therapy was associated
with a lower risk of death than that observed with
standard statin therapy. Data from the Cox propor-
tional hazards models are presented in Figure 3.
Standard versus No-Statin Cohort
There was a 32% lower risk of death in patients re-
ceiving a standard statin dose after hospital discharge
compared with their matched no-statin counterparts
(HR 0.68; 95% conﬁdence interval [CI] 0.53, 0.87;
P = 0.003). Risk of death was signiﬁcantly increased in
patients with heart failure (HR 1.37; 95% CI 1.01,
1.87; P = 0.04), occlusive cerebrovascular disease (HR
1.72; 95% CI 1.15, 2.55; P = 0.008), or cardiac valve
disorders (HR 1.63; 95% CI 1.19, 2.21; P = 0.002)
during index hospitalization compared with patients
without these conditions and was signiﬁcantly de-
creased in patients whose index event was a CABG
(HR 0.48; 95% CI 0.35, 0.66; P < 0.0001). Patients
with a diagnosis of heart failure in the preindex period
had an increased risk of death compared with those
without this diagnosis (HR 1.39; 95% CI 1.01, 1.92;
P = 0.04).
Intensive versus No-Statin Cohort
In the intensive statin therapy arm, the risk of death
was reduced by 42% compared with patients not
receiving statin therapy (HR 0.58; 95% CI 0.41, 0.82;
P = 0.002). An increased risk of death was experienced
by patients with an index event of nonfatal MI (HR
2.45; 95% CI 1.66, 3.63; P < 0.0001) or a preindex
diagnosis of ventricular arrhythmias (HR 2.17; 95%
Table 3 Baseline index CHD comorbidities occurring in more than 10% patients for all matched groups
Matched cohort: standard
vs. no-statin therapy (%)
Matched cohort: intensive
vs. no-statin therapy (%)
Matched cohort: intensive
vs. standard statin therapy (%)
Arteriosclerosis 79.3 81.5 86.7
Lipid disorders* 45.0 49.8 53.6
Hypertension 45.4 46.2 43.5
Diabetes 24.9 25.3 23.2
Angina pectoris 22.5 22.6 22.5
Heart failure 17.9 15.7 13.7
Cardiac valve disorders 12.2 10.6 9.0
*In the 1-year preindex period, 100% of patients had a diagnosis or treatment for lipid disorders. For instance, in the standard versus no-statin matched group, 67% of patients
had a diagnosis of lipid disorders, and 33% had a prescription for a lipid-lowering therapy but no actual diagnosis of lipid disorders in this period. The number of patients with
a lipid disorder drops to 45% to 54% during hospitalization for an index event because this diagnosis was not made at this particular point in time for a number of these patients.
The maximum length of stay for the index hospitalization was 30 days, so the time period to observe the lipid disorder was shorter and this may have contributed to the lower
diagnosis rate.
There were no signiﬁcant differences between the arms within any of the three matched groups in the incidence of index comorbidities occurring in more than 10% of patients.
CHD, coronary heart disease.
Figure 3 Crude mortality rates (A) and Cox proportional hazard analyses (B) of statin groups versus no-statin therapy and of intensive versus standard
statin therapy. Both standard and intensive statin therapies were associated with signiﬁcant reductions in the rate of all-cause mortality compared with
no-statin therapy. In addition, intensive statin therapy was associated with a further reduction compared with standard statin therapy. *P = 0.003, standard
statin therapy versus no statin; **P = 0.002, intensive statin therapy versus no statin; ***P = 0.02, intensive versus standard statin therapy.
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CI 1.24, 3.78; P = 0.006) compared with patients
without these index events.
Intensive versus Standard Statin Cohort
Patients who received intensive statin therapy after dis-
charge experienced a 29% lower risk of death than
patients who received standard statin therapy (HR
0.71; 95% CI 0.53, 0.95; P = 0.02). Higher mortality
risk was observed in patients with a diagnosis of cor-
onary artery disease (HR 2.41; 95% CI 1.26, 4.60;
P = 0.008) or heart failure (HR 1.67; 95% CI 1.15,
2.42; P = 0.007) in the preindex period compared
with those without these diagnoses. There was also a
greater risk of death in patients with an index event of
nonfatal MI (HR 1.61; 95% CI 1.03, 2.53; P = 0.04)
or a diagnosis of cardiac valve disorders at index hos-
pitalization (HR 1.55; 95% CI 1.04, 2.31; P = 0.03)
than in patients without these events at index, and a
lower risk of death was observed in patients with a
CABG (HR 0.44; 95% CI 0.27, 0.72; P = 0.001) as the
index event.
Conclusions
This study builds on previous retrospective claims
analyses examining LDL-C-lowering and goal attain-
ment as proxies for good clinical management of dys-
lipidemia and CHD. We identiﬁed patients from a
medical and pharmacy claims database who were hos-
pitalized for a CHD event and had been diagnosed
with or treated for dyslipidemia in the previous
12 months. By evaluating the impact of statin therapy
on all-cause mortality in a managed-care population,
this study evaluates a more clinically meaningful out-
come than previous studies. Analyses showed that
patients treated with statins after a CHD event,
whether administered as standard or as intensive ther-
apy, experienced a signiﬁcantly reduced risk of death
compared with those not treated with statins and dem-
onstrate that  the  reductions  in  mortality  observed
in large scale, randomized, clinical trials of statins
[1,2,12] can also be observed in a real-world, man-
aged-care setting. In addition, intensive statin therapy
provided a signiﬁcant risk reduction in all-cause mor-
tality over and above the beneﬁt seen with standard
statin therapy.
To date, statin trials that have compared mortality
rates with intensive versus standard therapy in patients
with ACS have not been designed to detect signiﬁcant
differences in this end point between the two treatment
groups. In the Myocardial Ischemia Reduction with
Aggressive Cholesterol Lowering (MIRACL) trial,
ACS patients randomized to atorvastatin 80 mg/day
experienced a nonsigniﬁcant 6% reduction in all-cause
mortality relative to patients randomized to placebo
and usual care [4]. Nevertheless, follow-up duration in
this trial was only 16 weeks, which likely accounts for
the inability of this study to detect large reductions in
all-cause mortality. The mean follow-up period was
approximately 2 years in both the PROVE IT–TIMI
22 [8] and the A to Z trials [21] and, as a result, larger
percent reductions in all-cause mortality were ob-
served in these trials than in the MIRACL trial with its
shorter follow-up period. Both PROVE IT–TIMI 22
and A to Z yielded trends toward greater reductions in
all-cause mortality in the intensive versus the standard
therapy groups. In the PROVE IT–TIMI 22 trial, all-
cause mortality was reduced by 28% in patients ran-
domized to atorvastatin 80 mg/day relative to those
randomized to more moderate pravastatin 40 mg/day
(P = 0.07) [8] and, in Phase Z of the A to Z trial, a
21% relative reduction in all-cause mortality was ob-
served with an intensive statin regimen (simvastatin
40 mg/day for 1 month, followed by simvastatin
80 mg thereafter) compared with a delayed conserva-
tive statin regimen (placebo for 1 month, followed by
simvastatin 20 mg/day thereafter) (P = 0.08) [21].
Clinical trial data on mortality rate comparisons
between intensive and moderate lipid-lowering ther-
apy in patients with chronic CHD are available from
the TNT and IDEAL studies [6,22]. Although TNT did
not yield a relative difference in the rate of all-cause
mortality between patients randomized to the two
treatment groups (atorvastatin 80 mg vs. atorvastatin
10 mg) [6], the mortality rate in the TNT trial was very
low (<6%) and in both the intensive and standard
arms of TNT was lower than that recorded in either
the placebo or active treatment arms of previous
major secondary prevention statin trials (all > 8%) [1–
3,12,23]. This low mortality rate reduced the power of
the study to detect a signiﬁcant effect between the two
groups. IDEAL randomized CHD patients to atorvas-
tatin 80 mg or simvastatin 20 to 40 mg [22]. Reduc-
tions in mortality with atorvastatin versus simvastatin
did not reach signiﬁcance.
Nevertheless, the data from the current study
suggest that, in a real-world setting, intensive statin
therapy is associated with signiﬁcant reductions in
mortality rates compared with patients who receive
standard statin therapy in a population containing
both ACS patients and patients with chronic CHD.
The current study also highlights gaps in the treat-
ment of patients with or at risk for CHD. All matched
patients had pre-existing dyslipidemia, yet 43% of
patients in the standard versus no-statin therapy
cohort had not received lipid-lowering therapy before
the index event. Although 75% of patients in the inten-
sive versus standard statin therapy cohort had received
lipid-lowering therapy beforehand, this still represents
a treatment gap of 25%. Intensive statin therapy may
be a particularly urgent priority in patients experienc-
ing nonfatal MI, since in the intensive versus no-statin
and intensive versus standard statin therapy cohorts,
patients experiencing nonfatal MI had a greater risk of
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death than those whose index event was not a nonfatal
MI.
Nevertheless, there are limitations in any studies
based purely on data from a retrospective administra-
tive claims database, which have to rely on the accu-
racy of the database records. In this study, the records
were quality checked and bias was minimized through
including only health plans that had submitted data
for all members. Nevertheless, the database contained
only patients enrolled in third-party payer plans and
the study included patients older than 65 years only if
they were covered by Medicare risk, and to this extent
the database may have had a demographic bias. More-
over, although a rigorous propensity matching proce-
dure was implemented, no patient is ever identical to
another and the possibility always remains that an
important systematic variable may have been over-
looked. Analyses were based on prescription/medical
claims data alone and no laboratory data were avail-
able, so the study is unable to make any conclusions
about the potential effects of greater LDL-C lowering
in the intensive statin regimens.
Death was deﬁned by using a claims-based proxy
method and this may have led to inaccurate estimates
of actual mortality rates. Indeed, the crude mortality
rates in this study (Fig. 1a) are lower than the typical
overall mean rate of approximately 11% observed in
recent placebo-controlled clinical trials of statins [1–
3,12,23]. The lower mortality rate in this study may be
due to the use of cardiovascular-related coding criteria
to determine death, placing an emphasis on CVD
death.
Nevertheless, the results from the current study are
supported by reports of similar rates in the reduction
of all-cause mortality with statin versus no-statin ther-
apy in other database studies. For example, in a study
of patients discharged from hospital after their ﬁrst MI
and followed for a mean of 3.7 years, all-cause mor-
tality was reduced by 31% in patients treated with
statins during follow up compared with those who
were not [24]. In a case control analysis of patients
with a ﬁrst diagnosis of ischemic heart disease in an
8-year longitudinal database, those receiving statin
therapy experienced a 39% lower risk of death than
patients not receiving statins [25], and in a study of
patients with angiographically deﬁned signiﬁcant
CHD followed for a mean of 3.3 years, patients receiv-
ing statin therapy on hospital discharge aged younger
than 65 years experienced a 30% reduction in mortal-
ity, rising to a 50% reduction in patients older than
85 years, compared with their counterparts who did
not receive statin therapy [26]. These reductions in
mortality are comparable to the 32% and 42% reduc-
tions observed in the current study with standard and
intensive statin therapy, respectively, versus no-statin
therapy. Nevertheless, it is still possible that the mor-
tality reductions observed in the current study corre-
spond to cardiovascular mortality more than they do
to all-cause mortality.
Nevertheless, despite these study limitations, the
data revealed very clear beneﬁts of statin therapy in
patients hospitalized with a CHD event and yielded
evidence for a substantial reduction in mortality rates
with the initiation of intensive versus standard statin
therapy. In short, this study has demonstrated that the
advantages of statin therapy observed in clinical trials
can also be observed in a real-world, managed-care
setting. High risk CHD patients clearly beneﬁt from
intensive statin regimens.
We would like to acknowledge the signiﬁcant assistance of
Fiona Steinkamp (Envision Pharma Ltd) in the preparation
and editing of this article.
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